Vaccinex, INC.: directors' dealings · United States · SEC (Form 4)

About Vaccinex, INC.

Vaccinex, Inc. is a United States-based clinical-stage biotechnology company listed on the NASDAQ under the ticker VCNX. Headquartered in Rochester, New York, the company was founded in 1997 and focuses on discovering and developing targeted biologic therapies for serious diseases with significant unmet medical needs. For French-speaking investors in France, Belgium, and Switzerland, Vaccinex fits the profile of a high-risk, high-volatility small-cap biotech whose equity story is driven primarily by clinical data, financing needs, and regulatory milestones rather than by established commercial revenues. The company’s core strategy is built around inhibition of SEMA4D, a biological pathway linked to immune activation, inflammation, and disease progression in both oncology and neurodegenerative disorders. Vaccinex’s lead asset is pepinemab, an anti-SEMA4D antibody being advanced across several therapeutic areas, including Alzheimer’s disease, Huntington’s disease, and solid tumors such as non-small cell lung cancer. Historically, the company has also worked on other monoclonal antibody and vaccine programs, which underscores its long-standing expertise in biologics and immunology-oriented drug discovery. From a competitive standpoint, Vaccinex is still a development-stage company rather than a commercial-stage biotech. It does not yet have a mature marketed product portfolio, so its investment case depends on clinical validation, partner interest, and access to capital. In a sector dominated by large-cap pharmaceutical groups and better-capitalized biotech peers, Vaccinex’s market position is essentially that of a specialized innovator pursuing differentiated science in difficult indications. The key question for investors is whether its SEMA4D platform can translate into meaningful efficacy signals and a viable development path. Recent corporate developments have remained centered on clinical updates and financing actions. In 2024, Vaccinex reported progress and biomarker-related updates for pepinemab in early Alzheimer’s disease, while also pursuing transactions designed to fund ongoing development. More recently, the company disclosed that it had initiated a process to delist from the NASDAQ, with the common stock expected to trade on the OTC Markets after suspension. That is an important consideration for equity investors, because it affects liquidity, tradability, and often market perception. Overall, VCNX should be viewed as a speculative NASDAQ-listed United States biotechnology name whose valuation is highly sensitive to clinical execution, funding events, and listing status.